Prevention of chronic NSAID induced upper gastrointestinal toxicity (Q33978682)

30 July 2017

30 July 2017

0 references

1 reference

title

Prevention of chronic NSAID induced upper gastrointestinal toxicity (English)

1 reference

30 July 2017

Prevention of NSAID-induced gastroduodenal ulcers (English)

1 reference

30 July 2017

3

P Tugwell

2 references

30 July 2017

30 July 2017

4

P Tugwell

0 references

author name string

A Rostom

1

2 references

30 July 2017

30 July 2017

G Wells

2

2 references

30 July 2017

30 July 2017

V Welch

4

2 references

30 July 2017

30 July 2017

C Dube

5

2 references

30 July 2017

30 July 2017

J McGowan

6

2 references

30 July 2017

30 July 2017

C Dube

2

0 references

G Wells

3

0 references

V Welch

5

0 references

E Jolicoeur

6

0 references

J McGowan

7

0 references

language of work or name

English

0 references

publication date

1 January 2000

2 references

30 July 2017

Cochrane Database of Systematic Reviews

30 July 2017

2002

0 references

published in

2 references

30 July 2017

30 July 2017

issue

3

1 reference

30 July 2017

4

1 reference

30 July 2017

page(s)

CD002296

2 references

30 July 2017

Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti‐inflammatory drug users – a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Effect of ranitidine on gastroduodenal mucosal damage in patients on long-term non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Abolition by omeprazole of aspirin induced gastric mucosal injury in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Ag

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Estimation of a common effect parameter from sparse follow-up data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Developing optimal search strategies for detecting clinically sound studies in MEDLINE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Locating and appraising systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Meta-analysis in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

The file drawer problem and tolerance for null results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

NSAID gastroenteropathy: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002296

10.1002/14651858.CD002296

21 January 2018

Identifiers

DOI

2 references

30 July 2017

30 July 2017

1 reference

30 July 2017

1 reference